ZL 6201
Alternative Names: ZL-6201Latest Information Update: 16 Nov 2025
At a glance
- Originator ZAI Lab
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 06 Nov 2025 Zai Lab intends to submit an Investigational New Drug application for a global phase I study in Sarcoma and LRRC15-positive Solid tumours, in the fourth quarter of 2025
- 06 Nov 2025 Zai Labs plans a global phase I trial for Sarcoma and Solid tumours in USA (Parenteral)
- 25 Apr 2025 Pharmacodynamics and adverse events data from a preclinical trials in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)